-
Transplantation May 1996
Topics: Azathioprine; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents
PubMed: 8629313
DOI: 10.1097/00007890-199605150-00029 -
Journal of the European Academy of... Dec 2019
Topics: Alopecia Areata; Azathioprine; Drug Therapy, Combination; Humans; Methotrexate
PubMed: 31374131
DOI: 10.1111/jdv.15834 -
Ugeskrift For Laeger Dec 2007
Review
Topics: Antimetabolites; Azathioprine; Colitis, Ulcerative; Evidence-Based Medicine; Humans; Mercaptopurine; Remission Induction; Treatment Outcome
PubMed: 18211790
DOI: No ID Found -
Gastroenterologie Clinique Et Biologique Mar 2009
Topics: Azathioprine; Genotype; Humans; Methyltransferases
PubMed: 19200674
DOI: 10.1016/j.gcb.2008.12.005 -
Pharmacotherapy 1987This review discusses the pharmacokinetics, mechanism of action, clinical use, toxicities, drug interactions, and possible approaches for therapeutic monitoring of... (Review)
Review
This review discusses the pharmacokinetics, mechanism of action, clinical use, toxicities, drug interactions, and possible approaches for therapeutic monitoring of azathioprine (AZA). The drug has been used extensively in posttransplant immunosuppressive protocols. Its therapeutic use is hampered by the development of toxicities, however, especially leukopenia, which is a common criterion for dosage adjustment. Azathioprine is rapidly converted in the liver and erythrocytes to 6-mercaptopurine (6MP), which is eventually metabolized to inactive 6-thiouric acid (6TU). The terminal half-lives of AZA and 6MP are 50 and 74 minutes, respectively. While renal dysfunction does not alter the disposition of AZA, hepatic insufficiency attenuates the pharmacologic activity. Immunosuppression depends on the formation of active intracellular thiopurine ribonucleotides, although AZA itself may block antigen recognition. Individualization of AZA regimens by determining tissue concentrations of thioguanine nucleotides, and plasma concentrations of AZA, 6MP, or 6TU may improve the risk:benefit ratio.
Topics: Azathioprine; Graft Rejection; Humans; Kidney Transplantation
PubMed: 3324057
DOI: 10.1002/j.1875-9114.1987.tb04046.x -
Canadian Journal of Gastroenterology =... Sep 1997
Topics: Azathioprine; Humans; Immunosuppressive Agents; Patient Education as Topic
PubMed: 9347161
DOI: No ID Found -
Journal of Clinical Gastroenterology Jun 1990We evaluated the efficacy of azathioprine (Az) therapy in chronic ulcerative colitis (CUC) retrospectively in a clinic population from 1977 to 1987. The study was an...
We evaluated the efficacy of azathioprine (Az) therapy in chronic ulcerative colitis (CUC) retrospectively in a clinic population from 1977 to 1987. The study was an open one. Sixteen patients were treated with a total of 20 courses of Az. Mean dose of Az was 1.48 mg/kg/d (range 0.98-1.82). All patients were on oral prednisone at the initiation of Az therapy. Indications for Az were: inability to wean off steroids without symptoms of CUC (12/20), poor response to steroids (7/20), and steroid toxicity (1/20). Responses to Az occurred in 15/20 courses (12/16 patients). Two patients had side effects requiring Az discontinuation. The mean duration of follow-up was 52.6 months with no incidence of malignancies. We conclude that the use of Az in selected patients with CUC who are steroid resistant or steroid dependent may be both efficacious and safe.
Topics: Adolescent; Adult; Azathioprine; Colitis, Ulcerative; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prednisone; Recurrence; Retrospective Studies
PubMed: 2362095
DOI: 10.1097/00004836-199006000-00007 -
Therapeutic Drug Monitoring Feb 2017We describe the case of a pediatric patient on azathioprine therapy with previously undiagnosed homozygote thiopurine S-methyltransferase (TPMT) deficiency, resulting in...
We describe the case of a pediatric patient on azathioprine therapy with previously undiagnosed homozygote thiopurine S-methyltransferase (TPMT) deficiency, resulting in myelotoxic thiopurine metabolite levels. The patient was successfully treated with a very low azathioprine dose of 50 mg once a week (4% of standard dose), guided by frequent thiopurine metabolite measurement and a close clinical surveillance. We demonstrate that azathioprine therapy still might be an effective and safe therapeutic option in pediatric thiopurine S-methyltransferase-deficient IBD patients.
Topics: Adolescent; Azathioprine; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Monitoring; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Male; Purine-Pyrimidine Metabolism, Inborn Errors; Treatment Outcome
PubMed: 28081040
DOI: 10.1097/FTD.0000000000000366 -
British Medical Journal Jul 1970
Topics: Adrenocorticotropic Hormone; Adult; Aged; Azathioprine; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Pemphigus; Prednisone
PubMed: 4316981
DOI: 10.1136/bmj.3.5714.84 -
Archives of Dermatology Sep 1973
Topics: Azathioprine; Female; Humans; Pemphigus
PubMed: 4729767
DOI: No ID Found